Objective:

To rename polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to better reflect and address its endocrine and metabolic features.

Key Findings:

• PCOS affects an estimated 170 million women globally and remains underdiagnosed in up to 70% of cases.
• The term 'polycystic ovary syndrome' contributed to delayed diagnosis and stigma.
• The new name PMOS reflects the disorder's multisystem endocrine and metabolic biology.
• Insulin resistance and compensatory hyperinsulinemia were reported in 85% of affected patients, including 75% of lean patients.

Interpretation:

The renaming to PMOS aims to enhance understanding and treatment of the condition by emphasizing its broader implications beyond ovarian dysfunction, including metabolic and cardiovascular health.

Limitations:

• Disproportionate representation from higher-income regions may limit the applicability of findings to lower-income areas.
• Lower participation from Asia, Africa, and South America raises concerns about the global relevance of the consensus.
• Purposive nonprobability sampling may limit generalizability despite broad international engagement.

Conclusion:

The change to PMOS has significant implications for healthcare systems, policy, and research, advancing the understanding and treatment of the condition on a global scale.